spec sheet11 rows
PNC-27 is an experimental anticancer peptide engineered to destroy cancer cells while sparing normal ones, a striking selectivity that has made it one of the most intriguing peptides in cancer research [1][2]. It works by a novel mechanism: binding to the HDM-2 protein that cancer cells uniquely display on their membranes, then forming cytotoxic transmembrane pores that lyse the cell [1][2]. Built from a fragment of the tumor-suppressor p53 fused to a membrane-penetrating sequence, PNC-27 has eradicated tumors in mice, though its evidence remains entirely preclinical [3][7].
- Engineered from p53 to target cancer cell membranes
- Binds HDM-2 displayed on tumor cell surfaces
- Punches pores in cancer cells; normal cells largely spared
- Eradicated tumors in mice; human trials have not begun
- Active across solid and non solid tumor lines in vitro
- A model compound for membrane targeted anticancer peptides
- Its safety, effective dose, and side-effect profile in people are unknown
- In laboratory studies it selectively killed cancer cells while sparing normal cells, but this does not guarantee safety in humans
Overview
PNC-27 is a synthetic anticancer peptide, a 32-residue chimeric molecule that joins a fragment of the human tumor-suppressor protein p53 to a membrane-penetrating carrier sequence [2][3]. The active portion corresponds to residues 12-26 of p53, the region that binds the HDM-2 protein (the human homolog of MDM2, a negative regulator of p53), and this is linked at its carboxyl terminus to a transmembrane-penetrating domain, variously called a penetratin or membrane residency peptide, that allows the whole peptide to associate with cell membranes [1][5][7]. It was designed through computer-based molecular modeling by researchers at SUNY Downstate Medical Center and collaborating institutions, part of a program that also produced related peptides such as PNC-28 from p53 and anticancer peptides derived from the ras-p21 protein [7].
The defining and unusual property of PNC-27 is selectivity: in laboratory studies it kills a wide range of cancer cell lines, including breast, pancreatic, and leukemia cells, while leaving untransformed normal cells unharmed [1][6]. This selectivity is explained by the discovery that many cancer cells express HDM-2 in their plasma membranes, whereas normal cells generally do not; PNC-27 finds and binds this membrane-bound HDM-2 and induces membranolysis, killing the cell by necrosis rather than by the slower process of apoptosis [1][4]. Because the effect depends on membrane HDM-2 rather than on restoring p53 activity, PNC-27 can kill even cancer cells that have lost p53 entirely [5].
It is essential to understand that PNC-27 is an investigational research compound, not an approved drug or dietary supplement. All published evidence comes from in vitro cell culture and animal models, including reports that the peptide eradicated a highly malignant tumor in nude mice without apparent side effects; there are no completed human clinical trials establishing its safety or efficacy [7]. It is not approved by any drug regulator and is sold only as a research peptide, typically supplied as a lyophilized powder for laboratory use [7]. Much of the work has been carried out by a single consortium of investigators, and independent large-scale validation is still awaited [1][7].
- Because PNC-27 kills by forming physical pores in the membrane rather than by restoring p53 signaling, it is cytotoxic even to cancer cells that have lost the p53 gene entirely.
- High-resolution immuno-electron microscopy has actually visualized PNC-27 and HDM-2 arranged in ring-shaped pores lining the surface of treated cancer cells.
Mechanism
PNC-27 kills cancer cells through a membrane-lytic mechanism that is fundamentally different from that of most anticancer agents. Its p53-derived segment, corresponding to residues 12-26, is shaped to bind HDM-2, the protein that normally sits inside cells to restrain p53 [1]. The pivotal finding behind PNC-27 is that many cancer cells, unlike normal cells, express HDM-2 in their plasma membranes; PNC-27 targets this membrane-bound HDM-2, and structural studies show that the p53 residues of the adopt the same conformation whether bound to HDM-2 in solution or at the membrane, confirming HDM-2 as the docking target [1]. When untransformed cells were engineered to display full-length HDM-2 on their surface, they too became susceptible to PNC-27, directly demonstrating that membrane HDM-2 is what confers vulnerability [1].
Once anchored, the assembles into transmembrane pores. Immuno-electron microscopy of treated cancer cells revealed PNC-27 and HDM-2 arranged in roughly 1:1 ratios in layered, ring-shaped structures lining pores near the cell surface, while no such pores formed in normal fibroblasts [2]. These pores breach the membrane and cause rapid cell lysis, releasing lactate dehydrogenase as a marker of necrosis; in leukemia cell lines this necrotic killing occurred within about 4 hours of treatment [4]. Studies with a double-labeled showed that PNC-27 acts as the intact molecule rather than as cleaved fragments, and that its selective interaction with targets present only in cancer cell membranes prolongs its residence there [6]. The membrane-penetrating carrier sequence is critical to this outcome: without it, the p53 fragment alone drives the slower, apoptotic form of cell death instead of rapid necrosis [7].
The practical consequences of this mechanism are notable. Because killing depends on membrane HDM-2 and physical pore formation rather than on reactivating the p53 pathway, PNC-27 is cytotoxic even to p53-null cancer cells, inducing nearly complete killing of p53-deleted K562 leukemia cells while sparing normal leukocytes [5]. In animal studies, the eradicated a highly malignant tumor in nude mice with no apparent side effects, supporting its promise as an anti-tumor agent [7]. These results are consistent and mechanistically detailed, but they remain preclinical; the true efficacy, dosing, pharmacokinetics, and safety of PNC-27 in humans have not been established in clinical trials [5][7].
receptor fingerprint
Membrane-bound HDM-2Binds in a p53-like conformation
Cancer cell plasma membraneInduces pore formation
membranesDisrupts membrane integrity
Safetyrisks and cautions, not medical advice
PNC-27 is an experimental anticancer peptide studied only in laboratory and animal models, with no human clinical trials, no established safety, and no defined dosing. Its proposed mechanism involves disrupting cell membranes, which raises clear concerns about off-target damage to healthy cells if used in people, and its behavior in the human body is entirely uncharacterized. It should be regarded as an unproven research chemical, not a treatment.
History
PNC-27 was developed by Matthew Pincus, Josef Michl and collaborators at SUNY Downstate Medical Center and allied institutions, as part of a search for anticancer peptides derived from the tumor-suppressor protein p53. It is built from the p53 residues 12 to 26, the segment that binds HDM-2, fused to a membrane-penetrating carrier sequence, and its defining insight was that many cancer cells uniquely display HDM-2 in their plasma membranes. Over roughly two decades the group and clinical partners published detailed structural, cell-biology, and animal studies, including tumor eradication in nude mice, and the peptide has been advanced by NomoCan Pharmaceuticals. All of its evidence remains preclinical; PNC-27 has not been tested in human clinical trials.
Reputation
PNC-27 is one of the more intriguing peptides in cancer research because of its striking reported selectivity; it lyses a wide range of cancer cells while sparing normal cells that express little or no membrane-bound HDM-2. Investigators find its mechanism compelling and well documented, from immuno-electron microscopy of the transmembrane pores it forms to evidence that it kills even p53-null cancer cells, since its action depends on physical pore formation rather than on reactivating the p53 pathway. The honest and important limitation is that this entire body of work is preclinical; efficacy, dosing, pharmacokinetics, and safety in humans have not been established. As a research compound it stands out for the depth and internal consistency of its mechanistic story rather than for any clinical validation.
Subjective profileweighing the evidence above
Elegant in a dish and unproven everywhere else. There are no human trials, no established dose, and a membrane-lysing mechanism whose off-target behaviour in a person is entirely uncharacterised. Nobody with cancer should be using this in place of real treatment.
Where to buy
1 other outlet
Suppliers
Vendors carrying PNC-27, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
| supplier | size | price | $/mg |
|---|---|---|---|
| RUOlowest | 5mg | $52.00 | $10.40/mg |
| Limitless Biochem | 5 mg | $139.00 | $27.80/mg |
RUO
PNC-27
Limitless Biochem🌐
PNC-27
Research
- 2004first citedNMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is se…
- 2024most recentAnti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound…
- 1.Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
- 2.PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
- 3.NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
- 4.Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
- 5.The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
- 6.The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.
- 7.Anti-cancer peptides from ras-p21 and p53 proteins.
- 8.Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
- 9.Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells
- 10.Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes
10 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is PNC-27?
It is a chimeric research peptide that pairs a p53-derived HDM-2 binding segment with a membrane-penetrating domain to target cancer cells.
How does it kill cancer cells?
In studies it binds membrane-bound HDM-2, forms transmembrane pores, and disrupts mitochondria, leading to cell necrosis.
Why does it spare normal cells?
Many cancer cells display HDM-2 in their membranes while typical untransformed cells do not, which appears to underlie the selectivity.
Is it a treatment?
No; it is an experimental compound studied only in cell and animal models, with no established human use.
Adverse effects
- Its safety, effective dose, and side-effect profile in people are unknown
- In laboratory studies it selectively killed cancer cells while sparing normal cells, but this does not guarantee safety in humans
Notes and cautions
- PNC-27 is an experimental research peptide, not an approved medicine, and has not been tested in human clinical trials
- As an injectable research peptide, general injection risks such as irritation or infection would apply
- Product purity and identity from research-chemical suppliers are not guaranteed